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Not stated.
Sources searched to identify primary studies
Criteria used to ensure the validity of primary studies
Methods used to judge relevance and validity, and for extracting data
Number of primary studies included
Nine studies were included in the review, and the number of sources varied from one to four across different parameters used in the model.
Methods of combining primary studies
The results from primary studies were not combined. In the case where multiple estimates were available, the baseline value was selected by the authors.
Investigation of differences between primary studies
Differences between studies were not investigated.
Results of the review
Based on one published controlled trial, the efficacy of both drug therapies was determined be 0.965. In the cohort of presumptively treated women the prevalence of chlamydia infection was assumed to be 0.20, while the estimates in the literature ranged from 0.10 to 0.50. The compliance rate for multidose therapy was assumed to be 0.80 ranging from 0.50 to 0.80 in the literature. The risk of acute PID was found to be 0.20 and 0.06 for unsuccessfully and successfully treated women, respectively. Of acute PID cases, 0.14 were hospitalized and 0.86 received outpatient treatment. In the acute PID patients the probability of developing chronic pain, ectopic pregnancy, and infertility were 0.18, 0.06, and 0.20, respectively. Treatment rate for infertility was 0.25.
Methods used to derive estimates of effectiveness
Estimates of effectiveness were also derived from the authors' assumption and the opinion of experts.
Estimates of effectiveness and key assumptions
The authors assumed that the compliance rate for the single dose therapy was 100%. The authors reported that the risks ofscarring sequelae were partly obtained through expert opinion, but did not specify the methods used or which estimates were produced in this process.
Measure of benefits used in the economic analysis
The measure of effectiveness used in the economic analysis was the number of cases of pelvic inflammatory disease (PID) prevented. The quality of life associated with the outcome was not assessed. Direct costs included costs of drug treatment, and costs of treating cases of PID and its sequelae. Future treatment costs were discounted at an annual rate of 5%. Resource use quantities were not reported separately from costs. The costs of initial drug therapy included only the cost of drugs,and the cost of clinician time and diagnostic tests were assumed to be identical and hence were excluded from the analysis. The price for the study medication was obtained from interviews with two retail pharmaceutical chains and administrators of multiple publicly funded clinics. The cost boundary of the health care system was adopted in the study, but also a more limited perspective of a publicly funded clinic was used.
Direct costs

Currency
US dollars ($).
Sensitivity analysis
A sensitivity analysis was carried out in order to address the uncertainty in the data and the differences in clinic setting and population. A one-way simple sensitivity analysis was performed on prevalence of chlamydia trachomatis in presumptively treated population, doxycycline compliance rate, the cost of treating PID and its sequelae, probability of PID among both compliers and non-compliers, and the risk of PID sequelae.
Estimated benefits used in the economic analysis
In the cohort of 10,000 women with laboratory confirmed chlamydia infection, 270 incremental cases of PID could be prevented by treating with azithromycin rather that doxycycline. In the cohort of 10,000 presumptively treated women, azithromycin would prevent 54 additional cases of PID. Benefits were not discounted sinceacute PID was assumed to occur within 12 months from diagnosed chlamydia infection.
Cost results
From the perspective of the health care system, the additional costs of treating 10,000 patients with azithromycin was estimated to be $290,000, and the savings due to avoided future treatments were $1.2 million in the laboratory confirmed group and $247,000 in the presumptively treated group. Using the public health clinic perspective the additional treatment costs associated with azithromycin for both cohorts was estimated to be $220,000 with future savings of $29,000 in the lab-confirmed cohort and $5,670 in the presumptively treated cohort.
Synthesis of costs and benefits
In the lab-confirmed group the treatment with azithromycin appeared to be a cost saving alternativefrom the perspective of the health care system, while the incremental cost-effectiveness ratio, using the publicly funded clinic's perspective, was $709 per additional case of PID prevented. For the presumptive-treatment cohort the incremental costeffectiveness ratios were $792 and $3,969 for the entire health care system and the publicly funded clinic, respectively. The sensitivity analysis demonstrated that the presumptive-treatment strategy was sensitiveto the model assumption, especially to the rate of compliance and the prevalence of chlamydia. From the health care system's point of view the presumptive treatment becomes cost saving if the price of azithromycin decreases by 10%.
